The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

As promised back in February, Teva Pharmaceuticals has asked the U.S. Supreme Court to overturn its $235 million loss in the company’s long-running “skinny label” patent feud with GSK. The case, which ...

The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in long-term survivors of childhood cancer exposed to anthracycline compared with placebo, ...

WASHINGTON (Reuters) - GlaxoSmithKline Plc said on Friday it won U.S. approval to sell a new once- a-day formulation of its Coreg hypertension drug. The new version, Coreg CR, is designed to be ...

Maximum plasma concentrations of carvedilol occur 1-2 hours after oral administration. [9] Absolute bioavailability of carvedilol is approximately 23% due to extensive first-pass metabolism. [9] Food ...